Challenges and opportunities for the pharmaceutical benefits scheme

Medical Journal of Australia

Volumn 196, Issue 3, 2012, Pages 153-154

  Clarke, Philip M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ASTHMA; AUSTRALIA; CHRONIC PAIN; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; EDITORIAL; EXPIRATION DATE; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE POLICY; MEDICARE; PATENT; PHARMACEUTICAL BENEFIT SCHEME; PHARMACIST; PRESCRIPTION; SCHIZOPHRENIA;

AUSTRALIA; DRUG COSTS; FORMULARIES AS TOPIC; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; PATENTS AS TOPIC;

EID: 84857808959     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10092     Document Type: Editorial

References (10)

1. Senate Finance and Public Administration References Committee. The Government's administration of the Pharmaceutical Benefits Scheme. Canberra: Commonwealth of Australia, 2011. http://www.aph.gov.au/Senate/ committee/fapa_ctte/pharma_benefits_scheme/report/report.pdf (accessed Feb 2012).
2. Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust 2010; 192: 633-636.
3. Australian Government and Medicines Australia. Memorandum of understanding. September 2010. http://www.pbs.gov.au/industry/usefulresources/ memorandum/MOU-MA-Sep2010.pdf (accessed Jan 2012).
4. Medicare Australia. Explanation of PBS pricing. June 2011. Canberra: Australian Government, 2011. http://www.medicareaustralia.gov.au/provider/pubs/ program/files/2526-explanation-of-pbs-pricing.pdf (accessed Feb 2012).
5. Australian Government Department of Health and Ageing. National Health (Weighted average disclosed price-main disclosure cycle) Determination 2011 (No. PB 80 of 2011). http://www.comlaw.gov.au/Details/F2011L02702 (accessed Jan 2012).
6. Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia [letter]. Med J Aust 2011; 194: 53-54.
7. Ontario Ministry of Health. Update ad: Ontario Drug Benefit Formulary/ Comparative Drug Index No. 41. Effective January 19, 2012. http://www. health. gov.on.ca/english/providers/program/drugs/formulary/41_update _ad_20120111.pdf (accessed Jan 2012).
8. Pharmaceutical Management Agency (PHARMAC) (NZ). Notification: Approval of the listing of Dr Reddy's brand of atorvastatin. 14 September 2011. http://www.pharmac.govt.nz/2011/09/14/2011-09%20Dr%20Reddy%27s% 20Atorvastatin%20notification.pdf (accessed Jan 2012).
9. Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care costs. N Engl J Med 2012; 366: 201-204. Epub 2011 Dec 7.
10. Health and Social Care Information Centre, National Health Service (UK). Prescription cost analysis, England-2010. 27 April 2011. http://www.ic.nhs.uk/ statistics-and-data-collections/primary-care/prescriptions/prescription-costanalysis-england--2010 (accessed Jan 2012).